ライフサイエンスコーパス: Chagas

1 Chagas cardiomyopathy was associated (P<0.01) with male

2 Chagas disease (CD) affects over 300 000 people in the U

3 Chagas disease caused by Trypanosoma cruzi is a paradigm

4 Chagas disease causes a severe inflammatory dilated chro

5 Chagas disease is a chronic infection caused by Trypanos

6 Chagas disease is a chronic infection in humans caused b

7 Chagas disease is a deadly infection caused by the proto

8 Chagas disease is a neglected tropical disease caused by

9 Chagas disease is a neglected tropical disease with 6-7

10 Chagas disease is a well-known cause of cardiomyopathy i

11 Chagas disease is amongst the ten most important neglect

12 Chagas disease is caused by the intracellular protozoan

13 Chagas disease is caused by the parasite Trypanosoma cru

14 Chagas disease is caused by the protozoan parasite Trypa

15 Chagas disease is caused by the protozoan parasite Trypa

16 Chagas disease is caused by the protozoan Trypanosoma cr

17 Chagas disease is characterised by an acute phase, which

18 Chagas disease is currently prevalent in European countr

19 Chagas disease is endemic in Latin America and an emergi

20 Chagas disease is now an active disease in the urban cen

21 Chagas disease is one of the main public health issues i

22 Chagas disease is one of the major neglected diseases of

23 Chagas disease was diagnosed in 25 (19%) patients.

24 Chagas disease, a neglected tropical disease discovered

25 Chagas disease, caused by infection with the protozoan p

26 Chagas disease, caused by the eukaryotic (protozoan) par

27 Chagas disease, caused by the parasite Trypanosoma cruzi

28 Chagas disease, caused by the parasite Trypanosoma cruzi

29 Chagas disease, caused by the protozoan parasite Trypano

30 Chagas disease, caused by the protozoan parasite Trypano

31 Chagas disease, caused by the protozoan Trypanosoma cruz

32 Chagas disease, caused by Trypanosoma cruzi parasite, wa

33 Chagas disease, caused by Trypanosoma cruzi, is an impor

34 Chagas disease, characterized by acute myocarditis and c

35 Chagas disease, leishmaniasis and sleeping sickness affe

36 Chagas disease, which was once thought to be confined to

37 Chagas disease-associated cardiomyopathy is clinically s

38 Chagas heart disease is an inflammatory cardiomyopathy t

39 Chagas' disease is a zoonosis prevalent in Latin America

40 Chagas' disease is an important cause of cardiomyopathy

41 Chagas' disease, caused by the hemoflagellate protozoan

42 Chagas' disease, caused by the protozoan parasite Trypan

43 Chagas' heart disease (CHD), caused by the parasite Tryp

44 >100 years ago, much has been learned about Chagas disease pathogenesis; however, the outcome of T.

45 ritic cell-based immunotherapeutic for acute Chagas disease in an attempt to delay or prevent the car

46 peutic strategies for the treatment of acute Chagas disease are feasible and that this approach may w

47 evidenced by recent microepidemics of acute Chagas disease attributed to the consumption of parasite

48 substantially ameliorates symptoms of acute Chagas disease in a mouse model with no apparent toxicit

49 ty on parasitemia in a murine model of acute Chagas disease.

50 r efficacy studies in a mouse model of acute Chagas disease.

51 and is efficacious in a mouse model of acute Chagas disease.

52 utaneous infection in a mouse model of acute Chagas' disease.

53 Similarly, symptomatic acute Chagas' disease patients displayed increased serum conce

54 Prospective observational study where adult Chagas disease patients accepting to receive benznidazol

55 hylase (CYP51) were proven effective against Chagas, and antifungal drugs posaconazole and ravuconazo

56 oximately 8 million people in Latin America, Chagas disease is now becoming a serious global health p

57 gnoses included schistosomiasis (Africa) and Chagas disease (Americas).

58 ogenesis of dilated cardiomyopathy (DCM) and Chagas heart disease.

59 emic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in LA.

60 m of human African trypanosomiasis (HAT) and Chagas disease.

61 African sleeping sickness, leishmaniasis and Chagas disease.

62 fection, schistosomiasis, leishmaniasis, and Chagas disease, is being led by nonprofit product develo

63 panosomes are causative agents of Nagana and Chagas disease respectively, and speciated about 300 mil

64 hypertensive heart disease, nonischemic and Chagas cardiomyopathies, rheumatic heart disease, and co

65 nsible for human African trypanosomiasis and Chagas disease.

66 line HAT (Human African Trypanosomiasis) and Chagas chemical boxes, two collections grouping 404 non-

67 riate for further development toward an anti-Chagas disease clinical candidate.

68 ole, another L14DM inhibitor that is an anti-Chagas drug candidate.

69 es for developing an easy to synthesize anti-Chagas agent.

70 As Chagas disease continues to expand beyond tropical and s

71 rase chain reaction (RT-PCR) in asymptomatic Chagas carriers.

72 ls with chronic indeterminate (asymptomatic) Chagas' disease potently blocked invasion of Trk-bearing

73 In Latin America, cardiomyopathy caused by Chagas disease is endemic.

74 HF) with reduced ejection fraction caused by Chagas' disease, with other etiologies, in the era of mo

75 Our results demonstrated that cardiac Chagas patients have a lower intensity of expression of

76 Since the discovery of T. cruzi by Carlos Chagas >100 years ago, much has been learned about Chaga

77 Trypanosoma brucei are parasites that cause Chagas' disease and African sleeping sickness, respectiv

78 Trypanosoma cruzi causes Chagas disease (American trypanosomiasis), which threate

79 Trypanosoma cruzi (TC) causes Chagas disease, which in its chronic stage remains incur

80 infection, a protozoan parasite that causes Chagas disease in humans.

81 Trypanosoma cruzi, the parasite that causes Chagas disease, the elongated, flagellated trypomastigot

82 of genomic DNA from the parasite that causes Chagas disease, Trypanosoma cruzi, directly in whole, un

83 Trypanosoma cruzi, the parasite that causes Chagas disease.

84 Trypanosoma cruzi infection (which causes Chagas disease) is typically undiagnosed and persists if

85 rs for Disease Control and Prevention (CDC), Chagas disease (CD) may affect 1.31% of Latin American i

86 Chronic Chagas disease cardiomyopathy, caused by Trypanosoma cru

87 vidence of its effectiveness against chronic Chagas disease.

88 ical aspects of the disease, such as chronic Chagas disease without detectable cardiac pathology, as

89 OS] in the Treatment of Asymptomatic Chronic Chagas Disease [P05267] [STOP CHAGAS]: NCT01377480).

90 cardiac, digestive and asymptomatic) chronic Chagas disease manifestations.

91 0% of infected patients will develop chronic Chagas cardiomyopathy (CCC), an inflammatory cardiomyopa

92 in the pathogenesis of experimental chronic Chagas disease, favoring inflammation and fibrogenesis.

93 nt and severe manifestation of human chronic Chagas disease and is characterized by heart failure, ve

94 In chronic Chagas disease, RV systolic dysfunction is more commonly

95 an adjuvant therapy for treatment of chronic Chagas disease.

96 Chagas disease occur annually due to chronic Chagas disease cardiomyopathy (CCC), an inflammatory car

97 study included 158 individuals with chronic Chagas disease who underwent cardiac magnetic resonance.

98 kg/day for 60 days in 30 adults with chronic Chagas disease.

99 dysfunction (LVSD) in patients with chronic Chagas heart disease, while the val/val genotype was ass

100 ypanosomal activity in patients with chronic Chagas' disease.

101 present in the sera of patients with chronic Chagas' disease.

102 suicide, liver cancer, diabetes, cirrhosis, Chagas disease, African trypanosomiasis, melanoma, and o

103 mended for all cases of acute and congenital Chagas disease, reactivated infection, and chronic T cru

104 age with benznidazole to prevent congenital Chagas disease (CCD), as well as the usefulness of polym

105 omen of childbearing age prevents congenital Chagas disease.

106 since the 1990s, but symptomatic congenital Chagas disease still represents a significant, albeit ch

107 s against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmanias

108 cruzi seropositives, 120 (24%) had definite Chagas cardiomyopathy, and among 488 T cruzi seronegativ

109 ytotoxicity could play a role in determining Chagas disease progression.

110 te the possibility of using RDTs to diagnose Chagas disease, thereby decreasing the time to treatment

111 Each Chagas disease group displayed distinct gene expression

112 nocidal therapy in patients with established Chagas' cardiomyopathy is unproven.

113 th benznidazole in patients with established Chagas' cardiomyopathy significantly reduced serum paras

114 e Instituto Nacional de Infectologia Evandro Chagas database who were enrolled between Jan 1, 2000, a

115 cellular experiments, cures the experimental Chagas disease with 100% efficacy, and suppresses viscer

116 For Chagas disease, a more extensive validation of the test

117 rocycles can lead to useful cidal agents for Chagas disease.

118 goal of delivering a new drug candidate for Chagas disease are reported.

119 istry efforts to develop drug candidates for Chagas' disease.

120 tential to lead to new chemotherapeutics for Chagas disease.

121 Benznidazole is the drug of choice for Chagas disease.

122 d be a novel target for drug development for Chagas cardiomyopathy.

123 e to another, and present case estimates for Chagas disease came from various sources, including WHO

124 The US-based Center of Excellence for Chagas Disease performed an observational study on the s

125 Current therapeutic options for Chagas' disease are limited to benznidazole and nifurtim

126 sialidase (TcTS) is a key target protein for Chagas disease chemotherapy.

127 several vertebrate hosts is responsible for Chagas' disease in Latin America.

128 INTERPRETATION: Screening for Chagas disease in asymptomatic Latin American adults liv

129 against cruzain, a thiol protease target for Chagas disease, looking for reversible, competitive inhi

130 with at least three different techniques for Chagas disease, maintained at controlled low temperature

131 To discover new possible therapies for Chagas' disease, we evaluated against all Trypanosoma cr

132 drugs to develop an efficient treatment for Chagas disease.

133 o capture the TcVac2-induced protection from Chagas disease.

134 Only a minority of samples from Chagas disease patients possessed antibodies against rLb

135 were uninfected control patients and 120 had Chagas disease (1 group had asymptomatic disease, and 2

136 icular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) ha

137 r, 300 000 individuals are estimated to have Chagas disease in the United States.

138 f the 120 seropositives classified as having Chagas cardiomyopathy, only 31 (26%) presented with ejec

139 zi is a protozoan parasite that causes human Chagas' disease, a leading source of congestive heart fa

140 zi, the protozoan parasite that causes human Chagas' disease, induces a type I interferon (IFN) (IFN-

141 revent the deadly cardiac pathology in human Chagas disease is a desirable and currently unattained g

142 factor to prevent myocardial damage in human Chagas disease.

143 luding Trypanosoma cruzi, the agent of human Chagas disease.

144 soma cruzi leads to the development of human Chagas' disease, yet the functional contributions of the

145 BIA platform for in situ diagnosis of human (Chagas disease and human brucellosis) and animal (bovine

146 tial to fulfill the urgent need for improved Chagas disease chemotherapy.

147 associated with activation of DN T cells in Chagas disease and that CD1d blocking leads to downregul

148 onsible for prominent systemic congestion in Chagas disease.

149 tion have been used to study heart damage in Chagas disease.

150 ver, occurrence of primary RV dysfunction in Chagas disease remains controversial.

151 e associated with microthrombus formation in Chagas' disease and a known activator of iPLA2, increase

152 pathomechanism of sustained inflammation in Chagas disease.

153 gest that galectin-3 is strongly involved in Chagas disease, not only in the immune response against

154 contribute to increased protein nitration in Chagas' disease.

155 olvement of MBL/MASP2-associated pathways in Chagas' disease, it is currently unknown whether MBL pla

156 cardiomyopathy, the main clinical problem in Chagas' disease, has been extensively studied but is sti

157 Even with a reduction in Chagas disease prevalence to 0.05% and with large variat

158 Several biomarkers have been reported in Chagas heart disease (ChHD), but most are nonspecific fo

159 a neurotransmitter thought to play a role in Chagas' disease progression.

160 actome between miRNAs and their targetome in Chagas heart disease by integrating gene and microRNA ex

161 e in neuropathology, and/or lack thereof, in Chagas' disease patients.

162 sue relationship between T. cruzi infection, Chagas disease, and host glucose homeostasis.

163 verall, this work provides new insights into Chagas disease pathogenesis and presents an analytical c

164 The most threatening trypanosomiasis is Chagas disease, affecting up to 12 million people in the

165 investigated include malaria, leishmaniasis, Chagas' disease, roundworm, whipworm, pinworm, Chinese l

166 ac pathology in a BALB/c mouse model of live Chagas disease.

167 on, AhR influences the development of murine Chagas disease by modulating ROS production and regulati

168 IC50 at 11.9 and 17.2 muM against neglected Chagas' disease causing Trypanosoma cruzi, respectively.

169 with Trypanosoma cruzi, the causal agent of Chagas cardiomyopathy, we observed a sudden switch from

170 osoma cruzi, which is the causative agent of Chagas disease and is a promising target for the develop

171 Trypanosoma cruzi (the etiological agent of Chagas disease) adapting via trade-off among three diffe

172 rypanosoma cruzi is the etiological agent of Chagas disease, a neglected and emerging tropical diseas

173 Trypanosoma cruzi is the causative agent of Chagas disease, and infects 5-8 million people in Latin

174 a cruzi ( T. cruzi ), the causative agent of Chagas disease, and the results of structure-activity in

175 Trypanosoma cruzi, the causative agent of Chagas disease, contains exclusively iron-dependent supe

176 Trypanosoma cruzi, the agent of Chagas disease, does not seem to control gene expression

177 Trypanosoma cruzi, the causative agent of Chagas disease, encodes for an alpha-carbonic anhydrase

178 by Trypanosoma cruzi, the causative agent of Chagas disease, has recently been described, with differ

179 of Trypanosoma cruzi, the etiologic agent of Chagas disease, have been highly inefficient, and no end

180 ected Trypanosoma cruzi, the causal agent of Chagas disease, implying the existence of evasion or tol

181 Trypanosoma cruzi, the etiological agent of Chagas disease, is a protozoan parasite with a complex l

182 infection, which is the etiological agent of Chagas disease, is associated with intense inflammation

183 Trypanosoma cruzi, the causing agent of Chagas disease, leads to an activation of the immune sys

184 a cruzi parasite is the etiological agent of Chagas disease, treatment is still plagued by limited ef

185 date tipifarnib kills the causative agent of Chagas disease, Trypanosoma cruzi, by blocking ergostero

186 Trypanosoma cruzi, the etiological agent of Chagas disease.

187 of Trypanosoma cruzi, the etiologic agent of Chagas disease.

188 te Trypanosoma cruzi, the causative agent of Chagas disease.

189 Trypanosoma cruzi is the etiologic agent of Chagas disease.

190 Trypanosoma cruzi is the causative agent of Chagas disease.

191 an Trypanosoma cruzi, the causative agent of Chagas disease.

192 an Trypanosoma cruzi, the causative agent of Chagas disease.

193 st Trypanosoma cruzi, the causative agent of Chagas disease.

194 cellular parasite and the causative agent of Chagas disease.

195 e: Trypanosoma cruzi, the causative agent of Chagas disease; Trypanosoma brucei, the causative agent

196 in Trypanosoma cruzi, the causative agent of Chagas' disease, has not been examined well.

197 Trypanosoma cruzi, the agent of Chagas' disease, infects a variety of mammalian cells in

198 Trypanosoma cruzi, the agent of Chagas' disease, promotes neuron survival through recept

199 or Trypanosoma cruzi, the causative agent of Chagas' disease, to escape from the host immune system a

200 in Trypanosoma cruzi, the causative agent of Chagas' disease.

201 an Trypanosoma cruzi, the causative agent of Chagas' disease.

202 Trypanosoma cruzi is the etiologic agent of Chagas' disease.

203 cruzi parasites are the causative agents of Chagas disease, a leading infectious form of heart failu

204 the clinical and epidemiological aspects of Chagas disease.

205 odified proteins may be useful biomarkers of Chagas' disease.

206 l and regional health and economic burden of Chagas disease from the societal perspective.

207 pecies as a means to alleviate the burden of Chagas disease in affected regions.

208 The economic burden of Chagas disease is similar to or exceeds those of other p

209 , there are approximately 8 million cases of Chagas disease in the southern cone of South America alo

210 Cardiomyopathy is a serious complication of Chagas' disease, caused by the protozoan parasite Trypan

211 ore attention and efforts towards control of Chagas disease.

212 e findings suggest that during the course of Chagas disease, CD8(+) T cells undergo a gradual loss of

213 merica and often leads to the development of Chagas disease.

214 disease penetrance and prognostic factors of Chagas cardiomyopathy among asymptomatic Trypanosoma cru

215 atients with indeterminate/digestive form of Chagas disease (35.7%) compared with those with Chagas c

216 hose with the indeterminate clinical form of Chagas disease, respectively.

217 e indeterminate or cardiac clinical forms of Chagas disease and whether IL-17 expression can be corre

218 yme, can cure the acute and chronic forms of Chagas disease.

219 f digestive pathologies of clinical forms of Chagas disease.

220 se and conclude with a view of the future of Chagas disease diagnosis, pathogenesis, therapy, and pre

221 eir partnership in the immunopathogenesis of Chagas disease, the chronic infection caused by the intr

222 study examined the prevalence and impact of Chagas cardiomyopathy (CCM) in a US population.

223 There is a substantial annual incidence of Chagas cardiomyopathy among initially asymptomatic T cru

224 in these areas that aid in the management of Chagas disease.

225 iomyocytes, as well as in the mouse model of Chagas disease, supporting the involvement of TcAPx-CcP

226 ssion of parasite burden in a mouse model of Chagas' disease.

227 Preclinical models of Chagas disease have demonstrated that antigen-specific C

228 cardiologists who adjudicated the outcome of Chagas cardiomyopathy.

229 role of autoimmunity in the pathogenesis of Chagas disease remain unanswered, the development of aut

230 e an important factor in the pathogenesis of Chagas disease.

231 rize what is known about the pathogenesis of Chagas heart disease and conclude with a view of the fut

232 parasite persistence and the pathogenesis of Chagas heart disease.

233 nctions and be important in the pathology of Chagas' disease.

234 stress may be important in the pathology of Chagas' disease.

235 t patients diagnosed in the chronic phase of Chagas disease already exhibit heart involvement, and th

236 In vivo tests on the acute phase of Chagas disease gave parasitemia inhibition values twice

237 t in vivo behavior during the acute phase of Chagas disease; and (iii) neither nonspecific toxicity n

238 against both the acute and chronic phases of Chagas disease was considered.

239 logy in both the acute and chronic phases of Chagas disease.

240 There is a high prevalence of Chagas disease among Latin American immigrants diagnosed

241 We found a 13% point prevalence of Chagas disease in a sample of New York City immigrants w

242 The pathological progression of Chagas disease is influenced by the infiltration and tra

243 Whether asymptomatic individuals at risk of Chagas disease living in Europe should be screened and t

244 dioprotective role during the acute stage of Chagas' disease.

245 4.4%) patients, 2 of them in early stages of Chagas disease.

246 we evaluated the congenital transmission of Chagas disease (CD) in a nonendemic area.

247 Oral transmission of Chagas disease has emerged in unpredictable situations i

248 Oral transmission of Chagas disease is considered when >1 acute case of febri

249 tential new drug target for the treatment of Chagas disease but has not been well studied.

250 tion, management, and etiologic treatment of Chagas disease.

251 Benznidazole is recommended for treatment of Chagas infection.

252 nd more effective drugs for the treatment of Chagas' disease.

253 ct physiology, but also is a major vector of Chagas disease, an illness that affects approximately se

254 with Rhodnius prolixus, the insect vector of Chagas disease, we show that an ovary dual oxidase (Duox

255 ne bug Rhodnius prolixus is a main vector of Chagas disease, which affects several million people, mo

256 the blood of various tetrapods and vector of Chagas' disease in humans, carries in its genome four di

257 American Trypanosomiasis or Chagas disease is a prevalent, neglected and serious deb

258 linical outcomes of the disease it provokes: Chagas disease (CD).

259 rformed an economic evaluation of systematic Chagas disease screening of the Latin American populatio

260 The Chagas' disease parasite Trypanosoma cruzi commonly infe

261 The Chagas' disease parasite Trypanosoma cruzi elicits a pot

262 o cross-sectional data of infestation by the Chagas disease vector Triatoma infestans in the city of

263 d neurotrophic factor (PDNF) produced by the Chagas' disease parasite Trypanosoma cruzi binds nerve g

264 ling the position of major clades (e.g., the Chagas disease vectors Triatominae).

265 The journey of the Chagas' disease parasite Trypanosoma cruzi in the human

266 Approximately 12000 deaths attributable to Chagas disease occur annually due to chronic Chagas dise

267 ction and oxidative stress may contribute to Chagas disease.

268 runcated into fragments that are specific to Chagas disease and have the potential to be used as diag

269 ites in the hearts of those who succumbed to Chagas disease.

270 ted therapeutic options to prevent and treat Chagas disease put 8 million people infected with T. cru

271 s as means of identifying new drugs to treat Chagas disease in the acute phase with greater activity,

272 azole are the front-line drugs used to treat Chagas disease, the most important parasitic infection i

273 leads for the development of drugs to treat Chagas disease.

274 of only 2 medications available for treating Chagas disease (CD) and currently the only drug availabl

275 liant squaramides as candidates for treating Chagas disease.

276 etiologic agent of American trypanosomiasis (Chagas disease), exhibiting IC(50) values in the nanomol

277 ich in humans cause African trypanosomiasis, Chagas disease, and leishmaniasis, respectively.

278 ding malaria, human African trypanosomiasis, Chagas disease, leishmaniasis, filariasis, and schistoso

279 nd mortality in areas of Latin America where Chagas disease is endemic and among infected individuals

280 n the USA (Lyme disease $2.5 billion), where Chagas disease has not been traditionally endemic, sugge

281 costs emanate from the USA and Canada, where Chagas disease has not been traditionally endemic.

282 al diseases (11 with schistosomiasis, 5 with Chagas' disease, and 10 with cutaneous leishmaniasis), a

283 Millions afflicted with Chagas disease and other disorders of aberrant glycosyla

284 Associations with Chagas cardiomyopathy were tested with multivariate logi

285 (9.3%) had ECG abnormalities consistent with Chagas cardiomyopathy; risk was higher for older women (

286 The patient newly diagnosed with Chagas disease should undergo a medical history, physica

287 ecies profile is altered in individuals with Chagas disease compared with healthy controls.

288 study RV systolic function in patients with Chagas disease using cardiac magnetic resonance.

289 in toxicity of benznidazole in patients with Chagas disease, determine the serum cytokine profile, an

290 e whole-blood transcriptome of patients with Chagas disease.

291 and CD1d by CD14(+) cells from patients with Chagas disease.

292 worse ventricular function in patients with Chagas disease.

293 antiinflammatory cytokines in patients with Chagas heart disease and those with the indeterminate cl

294 f IFN-gamma by DN T cells from patients with Chagas heart disease, which may be a potential target fo

295 andomized study involving 2854 patients with Chagas' cardiomyopathy who received benznidazole or plac

296 Patients with Chagas' disease remain asymptomatic for many years, pres

297 e events in nervous tissues of patients with Chagas' disease.

298 re released into the plasma of patients with Chagas' disease.

299 an heart samples obtained from subjects with Chagas disease who underwent heart transplantation showe

300 gas disease (35.7%) compared with those with Chagas cardiomyopathy (36.8%) (P=1.000).